Liraglutide in Adolescents With Type 1 Diabetes

Part of paid clinical trials in Buffalo, New York.

Sponsor
University at Buffalo
Study ID
NCT02516657
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
15 Years - 21 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an autoimmune disease that is usually diagnosed before the age of 20. Individuals with this disease are completely dependent on insulin for survival. While significant advances have been made in technological support for improving diabetes control, insulin remains the only effective treatment for Type 1 diabetes. Liraglutide is a long-acting glucagon-like peptide-1 analog. This drug is approved for the treatment of Type 2 diabetes in adults. This study will test the effect of liraglutide on blood sugar control in adolescents with Type 1 diabetes.

Key Dates

Start date
May 31, 2012
Status verified
Apr 2025
Primary completion
Aug 3, 2022
Completion
Aug 3, 2023

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide 0.6 mg
    Liraglutide 0.6 mg daily injection x 7 days

Primary Outcome Measure

Mean Weekly Blood Glucose [ Time Frame: Visit 1 (Before Liraglutide) at baseline (Day 0) vs. Visit 2 (After Liraglutide) on Day 7; ]

Locations (1)

FacilityCityStateZIPSite coordinators
UBMD Pediatrics, Division of Pediatric EndocrinologyBuffaloNew York14203-

Related coverage on Hipa.ai

Find similar trials in Buffalo, NY

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
UBMD Pediatrics, Division of Pediatric Endocrinology· Buffalo, NY

Related Studies